Technology Offerings

New Biomarkers miRNA-375 and miRNA-141 for Prostate Cancer

6% of all prostate cancer patients die due to their illness. However, 80% of all prostate cancer patients do not need therapy, since their cancers grow slowly. Since the mainly used marker (prostate-specific antigen, PSA) is also elevated in case of inflammatory processes or with benign prostatic hyperplasia, DKFZ inventors analysed serum samples and identified miRNA-375 and miRNA-141 as new biomarkers for high-risk tumors.

Further information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

Comments (0)

Write a comment